Transdermal delivery of dimethyl fumarate for Alzheimer’s disease: Effect of penetration enhancers
- 1 August 2017
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 465-473
Abstract
No abstract availableKeywords
Funding Information
- Center for Dermal Research CDR
- Iraqi Ministry of Higher Education and Scientific Research
This publication has 37 references indexed in Scilit:
- Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid EstersInternational Journal of Molecular Sciences, 2012
- Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 PathwayThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Neuroprotective strategies involving ROS in Alzheimer diseaseFree Radical Biology and Medicine, 2011
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Dimethylfumarate for PsoriasisAmerican Journal of Clinical Dermatology, 2010
- Formulation effects of topical emulsions on transdermal and dermal deliveryInternational Journal of Cosmetic Science, 2009
- Transdermal drug deliveryNature Biotechnology, 2008
- Rationale for transdermal drug administration in Alzheimer diseaseNeurology, 2007
- Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2007
- Dimethylfumarate for psoriasis: more than a dietary curiosityTrends in Molecular Medicine, 2005